Target intelligence / Profile preview

Puumala virus Gn-Gc envelope glycoprotein complex (PUUV Gn-Gc)

Target
PUUV Gn-Gc
Molecular classification
Receptor, Viral surface glycoprotein, Class II fusion protein, Other
01

Overview

The Puumala virus Gn-Gc envelope glycoprotein complex is a critical structural component of the Puumala orthohantavirus, which is the primary cause of nephropathia epidemica, a form of hemorrhagic fever with renal syndrome (HFRS) endemic to Europe and Russia (Wikipedia, 2024; NIH, 2021). This complex, composed of the Gn and Gc subunits, forms tetrameric spikes on the viral surface that are essential for host cell attachment and subsequent membrane fusion (MDPI, 2022; Cell Reports, 2016). The Gc subunit is characterized as a class II fusion protein, while the Gn subunit is thought to mediate receptor binding and protect the fusion loop of Gc in the prefusion state (eLife, 2020; Science Translational Medicine, 2022). As the primary target for neutralizing antibodies, the Gn-Gc complex is a focal point for the development of vaccines and therapeutic monoclonal antibodies (NIH, 2022). Experimental antibodies like ADI-42898 and P-4G2 work by binding to conserved or quaternary epitopes on the complex, thereby preventing the conformational changes necessary for viral entry (Science Translational Medicine, 2022; eLife, 2020). Despite its importance, the high genetic variability of the Gn subunit presents a significant challenge for the development of broad-spectrum therapeutics (Cell Reports, 2016).

Other names
Gn/Gc glycoprotein spikesGn-Gc hetero-octamersM polyproteinGlycoprotein G1Glycoprotein G2Puumala virus envelope glycoproteins
02

Mechanism of action

Neutralization of viral entry by blocking membrane fusion or receptor attachment through binding to the prefusion state of the glycoprotein complex (Science Translational Medicine, 2022; eLife, 2020).

03

Biological functions

Immune responseViral entryMembrane fusionViral assemblyHost cell attachmentOther
04

Disease associations

InfectionHemorrhagic fever with renal syndromeNephropathia epidemicaOther
05

Safety considerations

Antigenic variation and sequence diversity in the Gn subunit (Cell Reports, 2016)Lack of FDA-approved countermeasures (NIH, 2021)Risk of severe clinical outcomes including acute kidney injury and shock (NIH, 2021)
06

Interacting drugs

ADI-42898

1 more in the full profile.

07

Biomarkers

Interleukin-6 (IL-6)Pentraxin-3 (PTX3)Platelet countSerum creatinine

Beyond the preview

Go deeper on Puumala virus Gn-Gc envelope glycoprotein complex (PUUV Gn-Gc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Puumala virus Gn-Gc envelope glycoprotein complex (PUUV Gn-Gc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call